Biocon’s Q4 profit rises 27%

Biocon’s Q4 profit rises 27%
Comment E-mail Print Share
First Published: Thu, Apr 19 2007. 11 51 AM IST
Updated: Thu, Apr 19 2007. 11 51 AM IST
By Jay Shankar/Bloomberg
Biocon Ltd., India’s biggest biotechnology company, said consolidated net profit rose 27% in the fourth quarter while its net profit for the fiscal fourth quarter to March 31 rose 46% to Rs472.9 million.
Net income rose to Rs607 million from Rs478.3 million for the three months ended 31 March, the Bangalore- based company said in a release on 19 April. Sales rose 30% to Rs2.78 billion.Its net sales were Rs2.34 billion, up 29% from 1.82 billion a year earlier.
Consolidated net profit, which includes subsidiaries of the Bangalore-based group, rose 27% to Rs607 million. For the full year, net profit for the group was Rs1.58 billion, up 19%. Net sales gained 24% to Rs8.51 billion.
Biocon shares fell Rs1.9, or 0.4%,to Rs521.7 at 10:38 a.m. local time on the Bombay Stock Exchange on 19 April. The shares have gained 40% so far this year.
Biocon said revenue from the biopharmaceuticals and enzymes business grew 20% during the fiscal year, contributing 83% to operating revenues. Revenue from research services and licensing rose 63%, making up 17% of revenue.
“We will continue to make significant investments (in) our innovation pipeline and leverage the strategic initiatives to enter new business segments like oncology and nephrology,” said chief operating officer Arun Chandavarkar.
Comment E-mail Print Share
First Published: Thu, Apr 19 2007. 11 51 AM IST